VTGN
ANALYST COVERAGE7 analysts
HOLD
+49.1%upside to target
L $0.90
Med $0.95consensus
H $1.00
Buy
343%
Hold
457%
3 Buy (43%)4 Hold (57%)0 Sell (0%)
Full report →
Key MetricsTTM
Market Cap$21.18M
Revenue TTM$790.0K
Net Income TTM-$67.05M
Free Cash Flow-$60.39M
Gross Margin54.7%
Operating Margin-8847.8%
Net Margin-8486.8%
Return on Equity-109.7%
Return on Assets-103.1%
Debt / Equity0.03
Current Ratio4.67
EPS TTM$-1.59
PRICE
Prev Close
0.64
Open
0.64
Day Range0.62 – 0.67
0.62
0.67
52W Range0.43 – 5.14
0.43
5.14
4% of range
VOLUME & SIZE
Avg Volume
761.6K
FUNDAMENTALS
P/E Ratio
-0.3x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.57
High vol
TECHNICAL
RSI (14)
53
Bullish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 22
DEx-Dividend
In 90 days
Aug 19

VTGN News

About

VistaGen Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date, and has therapeutic potential in multiple CNS markets.

Industry
Pharmaceutical Preparation Manufacturing
Allen Easley CatoSenior Vice President of Integrated Drug Development
Mark J. GinskiSenior Vice President and Head of Chemistry, Manufacturing & Controls
Joshua PrinceChief Operating Officer
Mark Adrian McPartlandSenior Vice President of Investor Relations
Nick TresslerCFO, Principal Financial & Accounting Officer and Treasurer
Reid G. AdlerChief Legal Officer
Shawn K. SinghPresident, Chief Executive Officer & Director
Elissa CoteChief Corporate Development Officer
Michelle Peters WellingtonVice President of Communications
Trisha FitzmauriceSenior Vice President of Human Resources